Steve Hall, Ph.D.


Steve brings more than 35 years of pharmaceutical experience from both multinational pharmaceutical companies and biotech organizations to Lilly Ventures.  Prior to joining Lilly Ventures, Steve was SVP, Research and Development, at Serenex, Inc. where he was also a co-founder.  Steve also has held operational and leadership roles at Eli Lilly, Sphinx Pharmaceuticals, and Bristol-Myers Squibb in the areas of oncology, cardiovascular disease, and lead generation technologies.

Steve currently sits on the boards of Cavion Pharma, Esanex, FORMA Therapeutics, Hydra Biosciences, Kymera Therapeutics, Lysosomal Therapeutics and Nimbus Therapeutics.  In addition, Steve also serves as the CEO for Esanex.

Steve is the author of more than 40 papers and 60 patents. He received his B.S. in chemistry from Central Michigan University and his Ph.D. in organic chemistry from Massachusetts Institute of Technology.